

# **Virtual Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Study Design (Interventional, Observational, Expanded Access), By Indication (Oncology, Cardiovascular Disease, Others), By Phase (Phase 1, Phase 2, Phase 3, Phase 4), By Region, Competition By Type (Bladder, Piston, Diaphragm, and Spring), By Application (Blow Out Preventers (BOP), Mud Pumps, Offshore Rigs, and Others), By Deployment (Onshore, Offshore), By Region and Competition**

<https://marketpublishers.com/r/VB82BE99534CEN.html>

Date: October 2023

Pages: 172

Price: US\$ 4,900.00 (Single User License)

ID: VB82BE99534CEN

## **Abstracts**

The Global Virtual Clinical Trials Market was valued at USD 7.12 Billion in 2022 and is projected to experience strong growth during the forecast period, with a compound annual growth rate (CAGR) of 11.06% and expected to reach USD 13.26 Billion through 2028. This market is currently undergoing a significant transformation that is redefining the landscape of clinical research. Virtual clinical trials, also known as remote trials or decentralized trials, utilize advanced digital technologies to enhance the efficiency and patient-centric nature of research. By eliminating the need for physical study site visits, these trials offer remote enrollment, real-time monitoring, and data collection through digital platforms. The growth of this market is driven by factors such as rapid technological advancements, the demand for patient-centric trial designs, and the need for more streamlined trial execution. Virtual trials not only improve participant convenience and recruitment but also expedite decision-making through real-time access to data. While addressing regulatory and data security concerns remains critical,

the global virtual clinical trials market is poised to reshape the research landscape by providing more inclusive, efficient, and impactful solutions for advancing medical knowledge.

## Key Market Drivers

### Increasing Disease Burden

The rising prevalence of diseases is a key driver behind the expansion of the Virtual Clinical Trials (VCTs) market. As global populations face higher rates of various diseases, including chronic conditions and rare disorders, there is a pressing need for innovative and efficient research methods. Traditional clinical trials often grapple with challenges related to patient recruitment, retention, and accessibility, leading to prolonged trial timelines and delayed therapeutic advancements. Virtual Clinical Trials offer a compelling solution to address these issues. The growing disease burden drives researchers and pharmaceutical companies to explore new approaches that can expedite the drug development process. By leveraging digital technologies, VCTs enable researchers to reach a more diverse participant pool across geographic locations. This inclusivity improves the representation of real-world patients, making trial results more applicable to a wider population.

Additionally, the disease burden requires quicker and more agile research methods. VCTs, with their remote monitoring capabilities and real-time data collection, accelerate the pace of clinical research. The ability to collect data from participants in their natural environments, using wearable devices and telehealth solutions, ensures a continuous flow of information, enabling researchers to make timely decisions and adaptations to trial protocols. Moreover, certain diseases, such as rare disorders, often involve studies with small and widely dispersed patient populations. Traditional site-based trials can be logistically challenging and financially burdensome for such cases. VCTs overcome these barriers by allowing seamless participation regardless of geographical constraints, facilitating faster and cost-effective trials for diseases that may otherwise encounter significant obstacles. While the growing disease burden encourages the adoption of VCTs, various challenges need attention. Data security, patient privacy, regulatory compliance, and the establishment of standardized protocols are critical factors that must be carefully addressed. Collaborations between regulatory agencies, pharmaceutical companies, technology providers, and healthcare professionals are essential to ensure that VCTs maintain rigorous scientific and ethical standards.

Therefore, the escalating disease burden is a driving force behind the growth of the

Virtual Clinical Trials market. These trials offer a transformative approach to research, addressing the limitations of traditional methods while providing a patient-centric, efficient, and agile framework for advancing medical knowledge and expediting therapeutic breakthroughs. As the disease burden continues to rise, the adoption of Virtual Clinical Trials is set to play a pivotal role in reshaping the landscape of clinical research and enhancing patient outcomes globally.

### Surge in Virtual Clinical Trials (VCTs)

The recent surge in Virtual Clinical Trials (VCTs) signifies a significant paradigm shift in the field of clinical research, propelling market growth. Several factors contribute to this surge, reshaping the conduct of clinical trials and accelerating the adoption of virtual methodologies. A primary driver is the recognition of the limitations of traditional site-based trials, which often encounter challenges such as participant recruitment difficulties, high dropout rates, and geographical constraints. VCTs provide an innovative solution by leveraging digital technologies, enabling participants to engage remotely while maintaining real-time connections with researchers and healthcare providers. The COVID-19 pandemic played a pivotal role in driving the surge in VCTs. The crisis underscored the vulnerability of traditional trial models to disruptions and highlighted the urgent need for adaptable, remote research solutions. Virtual trials swiftly emerged as a resilient alternative, allowing trial continuity while prioritizing participant safety and data integrity. This demonstrated feasibility during the pandemic has catalyzed interest and confidence in the effectiveness of VCTs, resulting in increased adoption across therapeutic areas.

Furthermore, the surge in VCTs is fueled by advancements in digital health technologies, wearables, telemedicine, and electronic data capture systems. These tools empower researchers to remotely monitor participant health, collect real-time data, and ensure protocol compliance, all while reducing the burden on participants and eliminating the need for extensive travel. The resulting efficiency gains and enhanced participant experiences contribute to the growing popularity of VCTs among sponsors, investigators, and participants. Additionally, evolving guidance from regulatory agencies has played a pivotal role in boosting confidence in VCTs. Many agencies have recognized the potential of remote trials and have provided flexibility in trial design and data collection methods. This regulatory support has instilled trust in the validity and reliability of VCTs, encouraging more sponsors and researchers to explore this innovative approach.

As the surge in Virtual Clinical Trials continues, challenges related to data privacy,

patient engagement, and the integration of digital platforms with existing healthcare systems must be addressed. Collaborative efforts between regulatory bodies, technology providers, healthcare professionals, and pharmaceutical companies will be essential to ensure standardized practices and maintain ethical standards. Furthermore, the recent surge in Virtual Clinical Trials reflects a fundamental shift in clinical research practices, driven by the imperative for flexible, patient-centric, and technology-enabled approaches. The combined influence of the pandemic, technological advancements, and regulatory support has accelerated the adoption of VCTs, offering a glimpse into a future where remote research is not only feasible but also transformative in advancing medical knowledge and improving patient outcomes.

### Increasing Demand for Virtual Clinical Trials in Infrastructure and Construction Projects

The surge in healthcare digitization serves as a powerful catalyst driving the growth of the Virtual Clinical Trials (VCTs) market. As the healthcare sector embraces digital advancements, it seamlessly aligns with the principles and methodologies of virtual trials. The integration of electronic health records (EHRs), wearable devices, telehealth platforms, and data analytics creates a robust infrastructure for remote and real-time clinical research.

Healthcare digitization facilitates the remote collection of patient data, enabling VCTs to gather comprehensive information beyond traditional trial settings. Wearable devices and connected health solutions offer continuous monitoring, empowering participants to actively engage in their care. Telemedicine enables virtual study visits, enhancing convenience while maintaining standardized procedures. Additionally, the data-driven nature of digitization aligns with the analytical demands of VCTs. Researchers can leverage advanced analytics to extract meaningful insights from real-time data streams, enhancing trial efficiency and decision-making. However, ensuring data privacy, interoperability, and standardization remains crucial challenges to overcome for a seamless convergence of healthcare digitization and the expanding realm of VCTs. Together, these trends accelerate the adoption of VCTs, revolutionizing the landscape of clinical research for greater efficiency, accessibility, and patient-centricity.

### Key Market Challenges

#### Data Security and Privacy

Data security and privacy pose significant challenges within the Virtual Clinical Trials (VCTs) market due to the inherently digital and remote nature of these trials. As VCTs

involve the collection, transmission, and storage of sensitive patient health data through digital platforms, ensuring the utmost protection of patient information becomes paramount. The risk

of data breaches, unauthorized access, and potential exposure of personal health information raises concerns about the integrity and confidentiality of trial data. Maintaining compliance with stringent data protection regulations such as GDPR and HIPAA is a complex endeavor, particularly when dealing with diverse regulatory frameworks across different jurisdictions.

Addressing these challenges requires implementing robust encryption, secure data transmission protocols, and strict authentication mechanisms to prevent unauthorized access. Moreover, transparent and informed patient consent processes must be established, clearly outlining how their data will be collected, used, and protected. Collaborations between technology providers, cybersecurity experts, and regulatory bodies are necessary to develop comprehensive data security frameworks that instill confidence in both trial participants and stakeholders. The potential consequences of data breaches or privacy violations could not only disrupt trial operations but also erode trust in the entire VCT ecosystem. Thus, ensuring data security and privacy remains a critical factor in driving the successful adoption and expansion of Virtual Clinical Trials while safeguarding patient trust and trial integrity.

## Regulatory Compliance

Regulatory compliance poses a notable challenge in the Virtual Clinical Trials (VCTs) market due to the unique and evolving nature of these trials. Traditional clinical trial regulations were predominantly designed for site-based studies, creating a need to adapt existing frameworks to accommodate the remote and technology-driven aspects of VCTs. Ensuring that virtual trials adhere to established ethical standards, patient safety, data integrity, and scientific validity requires a delicate balance.

Different regulatory bodies across various countries may interpret and enforce regulations differently, leading to a lack of harmonization and potential confusion for sponsors and researchers. Additionally, the rapid pace of technological advancements and the diversity of virtual trial methodologies further complicate the establishment of standardized regulatory guidelines. Striking a balance between flexibility to encourage innovation and maintaining rigorous oversight to ensure patient safety is a challenge. To address these complexities, regulatory agencies must collaborate with industry stakeholders to develop clear and adaptable guidance that accommodates the nuances

of virtual trials. Sponsors and researchers need to proactively engage with regulatory authorities to seek clarity on compliance requirements, ensuring that trial protocols, data collection methods, and patient protections align with regulatory expectations. As the field of VCTs evolves, regulatory bodies will play a critical role in shaping the future by providing guidance that maintains ethical standards while fostering the growth and acceptance of this transformative approach to clinical research.

### Digital Infrastructure and Accessibility

Digital infrastructure and accessibility present challenges in the Virtual Clinical Trials (VCTs) market due to the reliance on advanced technologies. Ensuring participants have access to the necessary devices, stable internet connections, and digital literacy can create disparities in trial participation. Developing user-friendly platforms that accommodate diverse technological capabilities and addressing issues of connectivity in remote or underserved areas is crucial. Additionally, establishing interoperability between different digital tools and platforms, ensuring seamless data exchange, and maintaining data security require robust digital infrastructure. Overcoming these challenges is essential to enable widespread participation and reliable data collection in VCTs.

### Key Market Trends

#### Remote Monitoring and Wearables

The trend of remote monitoring and wearables significantly shapes the Virtual Clinical Trials (VCTs) market by revolutionizing data collection, enhancing patient engagement, and improving trial outcomes. Remote monitoring, facilitated by wearable devices and digital health technologies, enables participants to be continuously monitored in their everyday environments, providing real-time insights into their health status and treatment responses. This trend reduces the burden on participants by eliminating the need for frequent site visits and generates a more comprehensive dataset for researchers to analyze. Wearable devices, such as smartwatches and fitness trackers, offer a wealth of physiological and behavioral data, including heart rate, activity levels, sleep patterns, and more. These devices allow researchers to gather objective information beyond self-reported data, contributing to more accurate and reliable trial results. Furthermore, wearables can help detect subtle changes or early signs of adverse events, enabling timely interventions and enhancing patient safety.

This trend also fosters greater patient engagement by empowering participants to

actively monitor their health, creating a sense of ownership and involvement in their care. Participants are more likely to stay engaged throughout the trial due to the convenience of wearable devices and the potential for personalized feedback and insights. Researchers can gather data in real-world contexts, capturing how treatments impact participants' daily lives and resulting in more relevant and meaningful trial outcomes.

However, challenges related to data privacy, accuracy, device compatibility, and data integration into trial protocols must be addressed. As the trend of remote monitoring and wearables gains momentum, it holds the potential to reshape the VCTs landscape by providing richer, more contextualized data, improving patient experiences, and contributing to the overall efficiency and success of clinical trials in the digital age.

## Segmental Insights

### Study Design Insights

In 2022, the Observational study design segment is dominating the Virtual Clinical Trials (VCTs) market. Observational studies, which involve the collection and analysis of data without intervention or manipulation, align well with the remote and patient-centric nature of virtual trials. These studies can be conducted efficiently using digital platforms for data collection, real-time monitoring, and patient engagement. Their ability to gather real-world evidence while minimizing participant burden makes them particularly suitable for virtual methodologies. However, it's important to note that the dominance of specific study design segments can vary over time as the VCTs landscape evolves, and as regulatory bodies and technology continue to adapt to new trial approaches.

### Indication Insights

In 2022, the Oncology segment is anticipated to dominate the Virtual Clinical Trials (VCTs) market in the forecast period. Oncology trials often require a large and diverse participant pool, which virtual methodologies can efficiently accommodate through remote engagement and data collection. The ability to monitor patients in their natural environments, access real-time data, and include a wider range of demographics contributes to the prominence of oncology trials in the virtual space. However, market dynamics can evolve over time, and factors such as advancements in technology, regulatory changes, and therapeutic trends may influence the dominance of specific indication segments within the VCTs market.

## Regional Insights

Currently, North America is dominating the Virtual Clinical Trials (VCTs) market. This region possesses advanced healthcare infrastructure, technological capabilities, and established regulatory frameworks that facilitate the adoption of virtual methodologies. North America, with its robust pharmaceutical industry and regulatory support for innovative trial designs, leads in VCT implementation. Europe closely follows, benefiting from its strong research ecosystem and regulatory adaptations to accommodate virtual trials. While Asia Pacific and the Middle East show growing interest, challenges such as varying healthcare systems and regulatory landscapes can impact their market penetration. South America is also witnessing some adoption, but factors like limited infrastructure and resources may contribute to a slower pace of growth in the VCTs market.

## Key Market Players

Medable, Inc.

ICON, plc

Parexel International Corporation

Medidata Solutions Inc

Oracle Corp

Signant Health

Leo Laboratories Ltd

IQVIA Inc

PRA Health Sciences Inc

Clinical Ink Inc

## Report Scope:



In this report, the Global Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virtual Clinical Trials Market, By Study Design:

Interventional

Observational

Expanded Access

Virtual Clinical Trials Market, By Indication:

Oncology

Cardiovascular Disease

Others

Global Virtual Clinical Trials Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Virtual Clinical Trials Market.

Available Customizations:

Global Virtual Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

#### Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### **1. SERVICE OVERVIEW**

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### **2. RESEARCH METHODOLOGY**

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### **3. EXECUTIVE SUMMARY**

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### **4. VOICE OF CUSTOMERS**

### **5. GLOBAL VIRTUAL CLINICAL TRIALS MARKET OUTLOOK**

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Study Design (Interventional, Observational, Expanded Access)
  - 5.2.2. By Indication (Oncology, Cardiovascular Disease, Others)
  - 5.2.3. By Phase (Phase 1, Phase 2, Phase 3, Phase 4)

- 5.2.4. By Company (2022)
- 5.2.5. By Region
- 5.3. Market Map

## **6. NORTH AMERICA VIRTUAL CLINICAL TRIALS MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Study Design
  - 6.2.2. By Indication
  - 6.2.3. By Phase
  - 6.2.4. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States Virtual Clinical Trials Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Study Design
      - 6.3.1.2.2. By Indication
      - 6.3.1.2.3. By Phase
  - 6.3.2. Mexico Virtual Clinical Trials Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Study Design
      - 6.3.2.2.2. By Indication
      - 6.3.2.2.3. By Phase
  - 6.3.3. Canada Virtual Clinical Trials Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Study Design
      - 6.3.3.2.2. By Indication
      - 6.3.3.2.3. By Phase

## **7. EUROPE VIRTUAL CLINICAL TRIALS MARKET OUTLOOK**

- 7.1. Market Size & Forecast

- 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Study Design
  - 7.2.2. By Indication
  - 7.2.3. By Phase
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. France Virtual Clinical Trials Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Study Design
      - 7.3.1.2.2. By Indication
      - 7.3.1.2.3. By Phase
  - 7.3.2. Germany Virtual Clinical Trials Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Study Design
      - 7.3.2.2.2. By Indication
      - 7.3.2.2.3. By Phase
  - 7.3.3. United Kingdom Virtual Clinical Trials Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Study Design
      - 7.3.3.2.2. By Indication
      - 7.3.3.2.3. By Phase
  - 7.3.4. Italy Virtual Clinical Trials Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Study Design
      - 7.3.4.2.2. By Indication
      - 7.3.4.2.3. By Phase
  - 7.3.5. Spain Virtual Clinical Trials Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value
    - 7.3.5.2. Market Share & Forecast

- 7.3.5.2.1. By Study Design
- 7.3.5.2.2. By Indication
- 7.3.5.2.3. By Phase

## **8. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Study Design
  - 8.2.2. By Indication
  - 8.2.3. By Phase
  - 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
  - 8.3.1. China Virtual Clinical Trials Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Study Design
      - 8.3.1.2.2. By Indication
      - 8.3.1.2.3. By Phase
  - 8.3.2. India Virtual Clinical Trials Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Study Design
      - 8.3.2.2.2. By Indication
      - 8.3.2.2.3. By Phase
  - 8.3.3. South Korea Virtual Clinical Trials Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Study Design
      - 8.3.3.2.2. By Indication
      - 8.3.3.2.3. By Phase
  - 8.3.4. Japan Virtual Clinical Trials Market Outlook
    - 8.3.4.1. Market Size & Forecast
      - 8.3.4.1.1. By Value
    - 8.3.4.2. Market Share & Forecast

- 8.3.4.2.1. By Study Design
- 8.3.4.2.2. By Indication
- 8.3.4.2.3. By Phase
- 8.3.5. Australia Virtual Clinical Trials Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Study Design
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By Phase

## **9. SOUTH AMERICA VIRTUAL CLINICAL TRIALS MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Study Design
  - 9.2.2. By Indication
  - 9.2.3. By Phase
  - 9.2.4. By Country
- 9.3. South America: Country Analysis
  - 9.3.1. Brazil Virtual Clinical Trials Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Study Design
      - 9.3.1.2.2. By Indication
      - 9.3.1.2.3. By Phase
  - 9.3.2. Argentina Virtual Clinical Trials Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Study Design
      - 9.3.2.2.2. By Indication
      - 9.3.2.2.3. By Phase
  - 9.3.3. Colombia Virtual Clinical Trials Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value
    - 9.3.3.2. Market Share & Forecast



- 9.3.3.2.1. By Study Design
- 9.3.3.2.2. By Indication
- 9.3.3.2.3. By Phase

## **10. MIDDLE EAST AND AFRICA VIRTUAL CLINICAL TRIALS MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Study Design
  - 10.2.2. By Indication
  - 10.2.3. By Phase
  - 10.2.4. By Country
- 10.3. MEA: Country Analysis
  - 10.3.1. South Africa Virtual Clinical Trials Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Study Design
      - 10.3.1.2.2. By Indication
      - 10.3.1.2.3. By Phase
  - 10.3.2. Saudi Arabia Virtual Clinical Trials Market Outlook
    - 10.3.2.1. Market Size & Forecast
      - 10.3.2.1.1. By Value
    - 10.3.2.2. Market Share & Forecast
      - 10.3.2.2.1. By Study Design
      - 10.3.2.2.2. By Indication
      - 10.3.2.2.3. By Phase
  - 10.3.3. UAE Virtual Clinical Trials Market Outlook
    - 10.3.3.1. Market Size & Forecast
      - 10.3.3.1.1. By Value & Volume
    - 10.3.3.2. Market Share & Forecast
      - 10.3.3.2.1. By Study Design
      - 10.3.3.2.2. By Indication
      - 10.3.3.2.3. By Phase

## **11. MARKET DYNAMICS**

- 11.1. Drivers

## 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

### 12.1. Recent Developments

### 12.2. Product Launches

### 12.3. Mergers & Acquisitions

## **13. PESTLE ANALYSIS**

## **14. PORTER'S FIVE FORCES ANALYSIS**

### 14.1. Competition in the Industry

### 14.2. Potential of New Entrants

### 14.3. Power of Suppliers

### 14.4. Power of Customers

### 14.5. Threat of Substitute Product

## **15. COMPETITIVE LANDSCAPE**

### 15.1. Business Overview

### 15.2. Company Snapshot

### 15.3. Products & Services

### 15.4. Financials (In case of listed companies)

### 15.5. Recent Developments

### 15.6. SWOT Analysis

#### 15.6.1. Medable, Inc.

#### 15.6.2. ICON, plc

#### 15.6.3. Parexel International Corporation

#### 15.6.4. Medidata Solutions Inc

#### 15.6.5. Oracle Corp

#### 15.6.6. Signant Health

#### 15.6.7. Leo Laboratories Ltd

#### 15.6.8. IQVIA Inc

#### 15.6.9. PRA Health Sciences Inc

#### 15.6.10. Clinical Ink Inc

## **16. STRATEGIC RECOMMENDATIONS**

## I would like to order

Product name: Virtual Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Study Design (Interventional, Observational, Expanded Access), By Indication (Oncology, Cardiovascular Disease, Others), By Phase (Phase 1, Phase 2, Phase 3, Phase 4), By Region, Competition By Type (Bladder, Piston, Diaphragm, and Spring), By Application (Blow Out Preventers (BOP), Mud Pumps, Offshore Rigs, and Others), By Deployment (Onshore, Offshore), By Region and Competition

Product link: <https://marketpublishers.com/r/VB82BE99534CEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VB82BE99534CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970